<DOC>
	<DOCNO>NCT00303537</DOCNO>
	<brief_summary>The study evaluate use antidiabetic medicine metformin nonalcoholic fatty liver disease .</brief_summary>
	<brief_title>Metformin Non-Alcoholic Fatty Liver Disease</brief_title>
	<detailed_description>Nonalcoholic fatty liver disease ( NAFLD ) prevalent disorder associate insulin resistance . Metformin drug use several decade treatment diabetes mellitus . Metformin know improve insulin sensitivity . Some author report beneficial effect metformin NAFLD , others able reproduce finding . Only randomize controlled study publish far , still need controlled trial sufficient power ass efficacy metformin condition . The aim study see whether treatment metformin 26 week result reduction liver steatosis ( primary endpoint ) reduction grade inflammation non-alcoholic steatohepatitis ( NASH ) ( secondary endpoint ) .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Histologically proven NAFLD le 18 month prior inclusion . For pure steatosis , ALAT aspartate aminotransferase ( ASAT ) must elevate upper limit normal , impaired glucose tolerance diabetes mellitus type 2 must present . Body weight within +/ 5 kg compare weight time biopsy . Treatment 1 week metformin glitazones last 6 month inclusion . Treatment insulin . Hypersensitivity metformin . Treatment cimetidine . Heart failure require pharmacological treatment . Coronary heart disease ( New York Heart Association [ NYHA ] class 3 4 ) . Chronic obstructive lung disease ( moderate severe ) . Breastfeeding pregnant . Metabolic acidosis . Renal failure ( male [ ♂ ] : creatinine &gt; 135 micromol/L , female [ ♀ ] &gt; 110 micromol/L ) . Average alcohol consumption &gt; 24 g/day last year . Serum ALAT serum ASAT &gt; 5 x upper limit normal ( ULN ) screening . Cirrhosis . Platelets &lt; 100 000 . Haemochromatosis . Alfa1antitrypsindeficiency . Wilson 's disease . Thyroid dysfunction ( 0.2 mU/L &lt; thyroid stimulate hormone [ TSH ] &lt; 5.0 mU/L ) . Chronic infection hepatitis B C virus HIV . Autoimmune hepatitis ( antinuclear antibody [ ANA ] &gt; 1/256 smooth muscle antibody [ SMA ] &gt; 1/128 ) . Primary biliary cirrhosis ( antimitochondrial antibody [ AMA ] &gt; 1/64 ) . Primary sclerosing cholangitis . Previous participation another clinical trial last 6 month . Legal incapability .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>hepatitis</keyword>
	<keyword>metformin</keyword>
	<keyword>non-alcoholic fatty liver ( NAFLD )</keyword>
	<keyword>non-alcoholic steatohepatitis ( NASH )</keyword>
	<keyword>Nonalcoholic fatty liver disease</keyword>
</DOC>